Clinical Trial Search Results

All Clinical Trials

Records 1 - 704 of 704

1. Use of Definity® Contrast Agent for Ultrasound of Intraocular Tumors

Cancer Type

Eye Cancer

NCI ID

NCT01930968

Protocol IDs

IRB0003943

18F-Fluoride PET/CT Versus 99mTc-MDP Scanning for Detecting Bone Metastases: A Randomized, Multi-Center Trial to Compare Two Bone Imaging Techniques

Cancer Type

Prostate Cancer

NCI ID

NCT00882609

Protocol IDs

AMI-2008-01

A 2 Cohort, Non-comparative, Pivotal Study Evaluating the Efficacy of Tipifarnib in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC) With HRAS Mutations (AIM-HN) and the Impact of HRAS Mutations on Response to First Line Systemic Therapies for HNSCC (SEQ-HN)

Cancer Type

Head and Neck Cancer

NCI ID

NCT03719690

Protocol IDs

KO-TIP-007
NCI-2018-02535

A 5-year Longitudinal Observational Study of the Natural History and Management of Patients With Hepatocellular Carcinoma (HCC)

Cancer Type

NCI ID

NCT02954094

Protocol IDs

TARGET-HCC
NCI-2018-00316

A Biomarker-Driven Protocol for Previously Treated ALK-Positive Non-Squamous NSCLC Patients: The NCI-NRG ALK Protocol

Cancer Type

NCI ID

NCT03737994

Protocol IDs

NRG-LU003
NRG-LU003
NCI-2018-02486

A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL

Cancer Type

Leukemia

NCI ID

NCT01503632

Protocol IDs

Treatment Sites (1)

Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853

A Dose Escalation Study of Intensity Modulated Total Marrow Irradiation (IMRT-TMI) with Fludarabine as a Myeloablative Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Relapsed and Refractory Hematologic Malignancies

Cancer Type

Lymphoma, Myelodysplastic Syndromes (MDS)

NCI ID

NCT03696537

Protocol IDs

IUSCC-0652
NCI-2018-02544

A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)

Cancer Type

Unknown Primary

NCI ID

NCT01349881

Protocol IDs

Treatment Sites (4)

Nancy N. and J.C. Lewis Cancer & Research Pavilion at St. Joseph's/Candler
Savannah
Alaina Underberg
912-819-5778

Northeast Georgia Medical Center - Gainesville
Gainesville
Trena Davis
770-219-8822

Phoebe Cancer Center at Phoebe Putney Memorial Hospital
Albany
Dept of Clinical Research
(229) 312-0406

Piedmont Columbus Regional
Columbus

A Feasibility Trial of MLN4924 (Pevonedistat,TAK924) Given in Combination with Azacitidine, Fludarabine, and Cytarabine, in Children, Adolescents, and Young Adults with Relapsed or Refractory Acute Myeloid Leukemia or Relapsed Myelodysplastic Syndrome

Cancer Type

Myelodysplastic Syndromes (MDS)

NCI ID

NCT03813147

Protocol IDs

ADVL1712
ADVL1712
NCI-2019-00215

10.

A Genome-Wide Association Study in Participants Experiencing Breast Cancer Events in High-Risk Postmenopausal Women Receiving Selective Estrogen Receptor Modulators on NSABP Trials P-1 and P-2

Cancer Type

Breast Cancer

NCI ID

NCT00967239

Protocol IDs

MC083I
NCI-2009-01112
CDR0000638644
NSABP-MC083I

11.

A Global Randomized Multicenter Phase 3 Trial of JCAR017 Compared to Standard of Care in Adult Subjects With High-risk, Second-line, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas (TRANSFORM).

Cancer Type

Lymphoma

NCI ID

NCT03575351

Protocol IDs

Treatment Sites (1)

Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355

12.

A Groupwide Pilot Study to Test the Tolerability and Biologic Activity of the Addition of Azacitidine (NSC# 102816) to Chemotherapy in Infants with Acute Lymphoblastic Leukemia (ALL) and KMT2A(MLL) Gene Rearrangement

Cancer Type

Acute Lymphoblastic Leukemia

NCI ID

NCT02828358

Protocol IDs

Treatment Sites (2)

Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853

Curtis and Elizabeth Anderson Cancer Institute at Memorial University Medical Center
Savannah
Joni N. Shortt, RN, BSN, CCRC
912-350-8913

13.

A Master Protocol for Biomarker-Based Treatment of AML (The Beat AML Trial)

Cancer Type

Myelodysplastic Syndromes (MDS)

NCI ID

NCT03013998

Protocol IDs

BAML-16-001
NCI-2017-00278

14.

A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)

Cancer Type

Lung Cancer

NCI ID

NCT03851445

Protocol IDs

Treatment Sites (14)

Atlanta Cancer Care - Alpharetta
Alpharetta
Kristin Sieverding
770-777-1315

Atlanta Cancer Care - Conyers
Conyers
404-303-3355

Atlanta Cancer Care - Cumming
Cumming
Renee Gaiter
770-205-5292 x1041

Atlanta Cancer Care - Decatur
Decatur
404-303-3355

Atlanta Cancer Care - Stockbridge
Jonesboro
Andrena Jefferson
678 466-2069

Atlanta Cancer Care - Tower
Atlanta
404-303-3355

Georgia Cancer Specialists - Athens
Athens
Cynthia Pirkle

Georgia Cancer Specialists - Canton
Canton

Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242

Georgia Cancer Specialists - Kennestone
Marietta
Greta Dudley

Georgia Cancer Specialists - Macon-Coliseum
Macon
Sonia Hernandez
478-745-6130 x8152

Georgia Cancer Specialists - Stemmer
Decatur
Nina Patel
770-496-5555

Nancy N. and J.C. Lewis Cancer & Research Pavilion at St. Joseph's/Candler
Savannah
Alaina Underberg
912-819-5778

Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355

15.

A Multiarm, Open-label, Multicenter, Phase 1b / 2 Study to Evaluate Novel Combination Therapies in Subjects With Previously Treated Advanced EGFRm NSCLC

Cancer Type

Lung Cancer

NCI ID

NCT03381274

Protocol IDs

D6070C00004
NCI-2018-00476

16.

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications

Cancer Type

Multiple Primaries

NCI ID

NCT01351545

Protocol IDs

Treatment Sites (4)

Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853

Aflac Cancer and Blood Disorders Center of Children’s at Scottish Rite
Atlanta
Karen Querubin, BSN
404-785-2215

Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355

Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180

17.

A Multi-Center Biologic Assignment Trial Comparing Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive Care in Patients w/Intermediate-2 & High Risk Myelodysplastic Syndrome (BMT CTN #1102)

Cancer Type

Myelodysplastic Syndromes (MDS)

NCI ID

NCT02016781

Protocol IDs

BMTCTN1102
NCI-2015-00858
2U10HL069294-11
NCI-2014-00100
NCI-2015-00326

18.

A Multi-Center Phase I/II, Open-Label, Dose-Finding Pilot Study of the Combination of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Cancer Type

Multiple Myeloma

NCI ID

NCT01464034

Protocol IDs

Treatment Sites (1)

Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180

19.

A Multi-Center Phase Ib / II Trial of Nivolumab / Ipilimumab-Primed Immunotransplant for Relapsed / Refractory Diffuse Large B Cell Lymphoma Patients

Cancer Type

Lymphoma

NCI ID

NCT03305445

Protocol IDs

17-2164
NCI-2018-00677

20.

A Multicenter Phase II Study of Vaccines to Prevent Recurrence in Patients with HER-2 Positive Breast Cancer

Cancer Type

Breast Cancer

NCI ID

NCT03384914

Protocol IDs

MCC-19117
NCI-2018-00290

21.

A Multicenter Safety Study of Unlicensed, Investigational Cryopreserved Cord Blood Units Manufactured by the National Cord Blood Program and Provided for Unrelated Hematopoietic Stem Cell Transplantation of Pediatric and Adult Patients

Cancer Type

Hodgkin Lymphoma, Lymphoma, Non-Hodgkin Lymphoma, Skin Cancer (Non-Melanoma)

NCI ID

NCT01656603

Protocol IDs

6637-01
NCI-2016-01676

22.

A Multicenter Study of Hematopoietic Stem Cell Donor Safety and Quality of Life

Cancer Type

Quality of Life

NCI ID

NCT00948636

Protocol IDs

Treatment Sites (1)

Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180

23.

A Multicenter, Open Label Phase I/II Study of CEP-701 (Lestaurtinib) in Adults with Myelofibrosis

Cancer Type

Myelodysplastic Syndromes (MDS)

NCI ID

NCT00668421

Protocol IDs

104
NCI-2012-00298

24.

A Multicenter, Open Label, Phase III Extension Trial to Study the Long-term Safety and Efficacy in Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab Trial

Cancer Type

Unknown Primary

NCI ID

NCT03486873

Protocol IDs

3475-587
NCI-2018-01717
MK-3475-587
2017-004417-42

25.

A Multicenter, Open-Label Phase 1 Study of U3-1402 in Subjects With Metastatic or Unresectable EGFR-mutant Non-small Cell Lung Cancer

Cancer Type

Lung Cancer

NCI ID

NCT03260491

Protocol IDs

U31402-A-U102
NCI-2018-00060
2017-000543-41

26.

A Multicenter, Open-Label Phase 1b / 2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors

Cancer Type

Endometrial Cancer

NCI ID

NCT02501096

Protocol IDs

E7080-A001-111
NCI-2016-00529

27.

A Multicenter, Open-Label Study of CMX001 Treatment of Serious Diseases or Conditions Caused By dsDNA Viruses

Cancer Type

Bone and Soft Tissue (including Sarcoma)

NCI ID

NCT01143181

Protocol IDs

CMX001-350
1986

28.

A Multicenter, Open-label Study to Determine the Maximum Tolerated Dose, Assess the Safety and Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-220 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and/or Refractory Multiple Myeloma

Cancer Type

Multiple Myeloma

NCI ID

NCT02773030

Protocol IDs

CC-220-MM-001
NCI-2016-01463

29.

A Multi-Center, Phase 2, Open-label, Parallel Cohort Study of Efficacy and Safety of Duvelisib in Patients With Relapsed or Refractory Peripheral T Cell Lymphoma (PTCL)

Cancer Type

Lymphoma

NCI ID

NCT03372057

Protocol IDs

VS-0145-225
NCI-2018-00275

30.

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Trial of Tecemotide Versus Placebo in Subjects With Completed Concurrent Chemo-radiotherapy for Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)

Cancer Type

Lung Cancer

NCI ID

NCT02049151

Protocol IDs

Treatment Sites (1)

Phoebe Cancer Center at Phoebe Putney Memorial Hospital
Albany
Dept of Clinical Research
(229) 312-0406

31.

A Multi-center, Randomized, Double-blind, Placebo-controlled Phase III Trial of the FLT3 Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3 / ITD AML

Cancer Type

NCI ID

NCT02997202

Protocol IDs

Treatment Sites (1)

Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355

32.

A Multi-Center, Randomized, Open Label Trial to Evaluate the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV Iron and Compare the Safety, Effect on Quality of Life, and Resource Utilization of Injectafer vs. Intravenous Iron Standard of Care for the Treatment of Iron Deficiency Anemia (IDA) in an Infusion Center Setting

Cancer Type

Breast Cancer

NCI ID

NCT01950247

Protocol IDs

1VIT13032

33.

A Multicenter, Randomized, Open-label Phase 2 Study Evaluating the Safety and Efficacy of Three Different Regimens of Oral Panobinostat in Combination With Subcutaneous Bortezomib and Oral Dexamethasone in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma Who Have Been Previously Exposed to Immunomodulatory Agents

Cancer Type

Multiple Myeloma

NCI ID

NCT02654990

Protocol IDs

CLBH589D2222
NCI-2016-00234

34.

A Multicenter, Randomized, Open-Label Phase 2b Study to Investigate the Efficacy and Safety of Aldoxorubicin Compared to Topotecan in Subjects With Metastatic Small Cell Lung Cancer Who Either Relapsed or Were Refractory to Prior Chemotherapy

Cancer Type

Lung Cancer

NCI ID

NCT02200757

Protocol IDs

Treatment Sites (9)

Northwest Georgia Oncology Centers - Austell
Austell
Mary Gilley
770-281-5131

Northwest Georgia Oncology Centers - Bremen
Bremen
Mary Gilley
770-281-5131

Northwest Georgia Oncology Centers - Carrollton
Carrollton
Mary Gilley
770-281-5131

Northwest Georgia Oncology Centers - Cartersville
Cartersville
Mary Gilley
770-281-5131

Northwest Georgia Oncology Centers - Douglasville
Douglasville
Mary Gilley
770-281-5131

Northwest Georgia Oncology Centers - Jasper
Jasper
Mary Gilley
770-281-5131

Northwest Georgia Oncology Centers - Marietta
Marietta
Mary Gilley
770-281-5131

Northwest Georgia Oncology Centers - Paulding
Hiram
Mary Gilley
770-281-5131

Northwest Georgia Oncology Centers - Villa Rica
Villa Rica
Mary Gilley
770-281-5131

35.

A Multi-Center, Randomized, Phase III Study of Rituximab Versus Iodine I 131 Tositumomab Therapy for Patients With Relapsed Follicular Non-Hodgkin's Lymphoma

Cancer Type

Non-Hodgkin Lymphoma

NCI ID

NCT00078598

Protocol IDs

CCBX001-049

36.

A Multinational, Randomized, Open-Label Phase III Study of Custirsen (TV-1011/OGX-011) In Combination With Docetaxel Versus Docetaxel As A Second-Line Treatment In Patients With Advanced or Metastatic (Stage IV) Non-Small Cell Lung Cancer

Cancer Type

Lung Cancer

NCI ID

NCT01630733

Protocol IDs

TV1011-LC-303
2012-002447-14

37.

A Multi-site, Prospective, Observational Study in US Patients with Advanced Melanoma

Cancer Type

Melanoma

NCI ID

Protocol IDs

CA184-199
IMPULSE
BMS CA184-199

38.

A Non-randomized, Open-label, Multi-center, Phase I / II Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Copanlisib in Pediatric Patients With Relapsed / Refractory Solid Tumors or Lymphoma

Cancer Type

Bone and Soft Tissue (including Sarcoma), Ewing Sarcoma, Lymphoma, Neuroblastoma

NCI ID

NCT03458728

Protocol IDs

19176
NCI-2018-00809
2017-000383-15

39.

A Novel Method of Screening for Ovarian Cancer Using Gynecologic Fluids and Mucus

Cancer Type

NCI ID

NCT01787656

Protocol IDs

USA-MCI GON-1.04
NCI-2015-00690
13-005

40.

A Phase 1 / 1b First-In-Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IPI-549 Monotherapy and in Combination With Nivolumab in Subjects With Advanced Solid Tumors

Cancer Type

Unknown Primary

NCI ID

NCT02637531

Protocol IDs

IPI-549-01
NCI-2016-00132

41.

A Phase 1 / 1b, Open-Label, Dose-Escalation and Expansion Study of Entrectinib (RXDX 101) in Children and Adolescents With Recurrent or Refractory Solid Tumors and Primary CNS Tumors, With or Without TRK, ROS1, or ALK Fusions

Cancer Type

Neuroblastoma

NCI ID

NCT02650401

Protocol IDs

RXDX-101-03
NCI-2016-00924

42.

A Phase 1 / 2 Multicenter Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Subjects With Relapsed / Refractory Chronic Lymphocytic Leukemia

Cancer Type

Leukemia, Lymphoma

NCI ID

NCT03624036

Protocol IDs

KTE-C19-108
NCI-2018-02958
2018-001923-38

43.

A Phase 1 / 2 Open Label, Multicenter, Dose Escalation and Expansion Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM43239 in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)

Cancer Type

NCI ID

NCT03850574

Protocol IDs

HM-FLTI-101
NCI-2019-06837

44.

A Phase 1 / 2 Study of In Situ Vaccination With Tremelimumab and IV Durvalumab (MEDI4736) Plus the Toll-like Receptor Agonist PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers

Cancer Type

Melanoma

NCI ID

NCT02643303

Protocol IDs

LUD2014-011
NCI-2017-01766

45.

A Phase 1 / 2 Study of Oral LOXO-305 in Patients With Previously Treated Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (CLL / SLL) or Non-Hodgkin's Lymphoma (NHL)

Cancer Type

Leukemia, Lymphoma, Non-Hodgkin Lymphoma

NCI ID

NCT03740529

Protocol IDs

LOXO-BTK-18001
NCI-2019-02015

46.

A Phase 1 / 2 Study of Pembrolizumab plus Pralatrexate for Treatment of Relapsed or Refractory Peripheral T-Cell Lymphomas

Cancer Type

NCI ID

NCT03598998

Protocol IDs

17501
NCI-2018-01420

47.

A Phase 1 / 2 Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of the Oral EGFR / HER2 Inhibitor TAK-788 (AP32788) in Non-Small Cell Lung Cancer

Cancer Type

Lung Cancer, Unknown Primary

NCI ID

NCT02716116

Protocol IDs

AP32788-15-101
NCI-2016-00587
U1111-1217-7205

48.

A Phase 1 / 2 Study of the TRK Inhibitor LOXO-195 in Adult and Pediatric Subjects With Previously Treated NTRK Fusion Cancers

Cancer Type

NCI ID

NCT03215511

Protocol IDs

20810
NCI-2017-01629
2017-004246-20
LOXO-EXT-17005

49.

A Phase 1 / 2 Study of VX15 / 2503 in Children, Adolescents, or Young Adults with Recurrent or Relapsed Solid Tumors

Cancer Type

Bone and Soft Tissue (including Sarcoma)

NCI ID

NCT03320330

Protocol IDs

ADVL1614
ADVL1614
NCI-2017-01103

50.

A Phase 1 / 2, Multicenter, Dose-Escalation and Expansion Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Subjects With Relapsed or Refractory Multiple Myeloma

Cancer Type

Lymphoma, Multiple Myeloma

NCI ID

NCT03314181

Protocol IDs

M15-654
NCI-2018-00251
2017-002099-26

51.

A Phase 1 / 2, Multicenter, Open-label Study of FT-2102 as a Single Agent and in Combination With Azacitidine or Cytarabine in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome With an IDH1 Mutation

Cancer Type

Leukemia, Myelodysplastic Syndromes (MDS)

NCI ID

NCT02719574

Protocol IDs

2102-HEM-101
NCI-2016-00637

52.

A Phase 1 / 2, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 510 Monotherapy in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation and AMG 510 Combination Therapy in Subjects With Advanced NSCLC With KRAS p.G12C

Cancer Type

Unknown Primary

NCI ID

NCT03600883

Protocol IDs

20170543
NCI-2018-01725

53.

A Phase 1 / 2, Open-Label Study of ADXS-503 Alone and in Combination With Pembrolizumab in Subjects With Metastatic Squamous or Non-Squamous Non-Small Cell Lung Cancer

Cancer Type

Lung Cancer, Unknown Primary

NCI ID

NCT03847519

Protocol IDs

ADXS-503-101
NCI-2019-01784

54.

A Phase 1 / 2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies - (FIGHT-101)

Cancer Type

Myelodysplastic Syndromes (MDS)

NCI ID

NCT02393248

Protocol IDs

INCB 54828-101
NCI-2015-00611

55.

A Phase 1 / 2, Open-label, Multicenter, Dose Escalation and Dose Expansion Study of NKTR-262 in Combination With NKTR-214 and in Combination With NKTR-214 Plus Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumor Malignancies

Cancer Type

Melanoma

NCI ID

NCT03435640

Protocol IDs

17-262-01
NCI-2018-00619

56.

A Phase 1 / 2a Open-Label Study to Determine the Safety and Tolerability of ALRN-6924 in Patients With Advanced Solid Tumors or Lymphomas Expressing Wild-Type p53 Protein

Cancer Type

Lymphoma

NCI ID

NCT02264613

Protocol IDs

ALRN-6924-1-01
NCI-2015-00008
ALRN-200-01

57.

A Phase 1 / 2a Open-label Study to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-573 (Formerly TEV-48573) Administered Intravenously as a Single Agent in Patients With Refractory Multiple Myeloma

Cancer Type

Lymphoma, Multiple Myeloma

NCI ID

NCT03215030

Protocol IDs

TAK-573-1501
NCI-2017-01894
U1111-1195-8134
TV48573-ONC-10128

58.

A Phase 1 / 2a Study to Evaluate the Safety and Preliminary Efficacy of Ibrutinib and Pembrolizumab in Patients with Mantle Cell Lymphoma (MCL)

Cancer Type

Lymphoma

NCI ID

NCT03153202

Protocol IDs

17-0554
NCI-2017-01538

59.

A Phase 1 and Phase II and Re-Treatment Study of AZD6244 for Recurrent or Refractory Pediatric Low Grade Glioma

Cancer Type

NCI ID

NCT01089101

Protocol IDs

PBTC-029
PBTC-029
NCI-2012-03173
CDR667932
PBTC-029B

60.

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Cancer Type

Unknown Primary

NCI ID

NCT02817633

Protocol IDs

4020-01-001
NCI-2016-01254

61.

A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors

Cancer Type

Unknown Primary

NCI ID

NCT02715284

Protocol IDs

4010-01-001
NCI-2016-01910

62.

A Phase 1 Dose-escalation Study of Radio- Labeled Antibody, FF-21101(90Y) for the Treatment of Advanced Cancer

Cancer Type

NCI ID

NCT02454010

Protocol IDs

FF21101US101
NCI-2015-01552

63.

A Phase 1 Multicenter, Open-label Study to Assess the Safety, Pharmacokinetics and Preliminary Efficacy of CC-92480 in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma

Cancer Type

Lymphoma, Multiple Myeloma

NCI ID

NCT03374085

Protocol IDs

CC-92480-MM-001
NCI-2018-00132
U1111-1205-3650
2017-001236-19

64.

A Phase 1 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI9447 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors

Cancer Type

Unknown Primary

NCI ID

NCT02503774

Protocol IDs

Treatment Sites (5)

Piedmont Cancer Institute - Atlanta
Atlanta

Piedmont Cancer Institute - Fayetteville
Fayetteville

Piedmont Cancer Institute - Newnan
Newnan

Piedmont Cancer Institute - Stockbridge
Stockbridge

Piedmont Henry Hospital
Stockbridge

65.

A Phase 1 Multiple Ascending Dose Study of DS-3201b in Subjects With Lymphomas

Cancer Type

Leukemia, Lymphoma, Non-Hodgkin Lymphoma

NCI ID

NCT02732275

Protocol IDs

DS3201-A-J101
NCI-2019-00366

66.

A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb®14045 in Patients With CD123-Expressing Hematologic Malignancies

Cancer Type

Leukemia, Lymphoma, Myelodysplastic Syndromes (MDS), Skin Cancer (Non-Melanoma)

NCI ID

NCT02730312

Protocol IDs

XmAb14045-01
NCI-2016-00916

67.

A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb®18087 in Subjects With Advanced Neuroendocrine and Gastrointestinal Stromal Tumors

Cancer Type

Colon/Rectal Cancer

NCI ID

NCT03411915

Protocol IDs

XmAb18087-01
NCI-2018-00217

68.

A Phase 1 Multiple Dose Study to Evaluate the Safety and Tolerability of XmAb®20717 in Subjects With Selected Advanced Solid Tumors

Cancer Type

Endometrial Cancer

NCI ID

NCT03517488

Protocol IDs

XmAb20717-01
NCI-2018-00935
DUET-2

69.

A Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®22841 Monotherapy and in Combination With Pembrolizumab in Subjects With Selected Advanced Solid Tumors (DUET-4)

Cancer Type

Breast Cancer, Cervical Cancer, Colon/Rectal Cancer, Eye Cancer, Head and Neck Cancer, Kidney Cancer, Lung Cancer, Melanoma, Pancreatic Cancer, Prostate Cancer , Skin Cancer (Non-Melanoma), Stomach/ Gastric Cancer, Unknown Primary

NCI ID

NCT03849469

Protocol IDs

XmAb22841-01
NCI-2019-02498
DUET-4

70.

A Phase 1 Multiple-Dose Study to Evaluate the Safety and Tolerability of XmAb®23104 in Subjects With Selected Advanced Solid Tumors

Cancer Type

Lung Cancer

NCI ID

NCT03752398

Protocol IDs

XmAb23104-01
NCI-2019-00828
DUET-3

71.

A Phase 1 Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 701 in Subjects With Multiple Myeloma

Cancer Type

Lymphoma, Multiple Myeloma

NCI ID

NCT03287908

Protocol IDs

20170122
NCI-2017-02084
2017-001997-41

72.

A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies

Cancer Type

Lymphoma, Multiple Myeloma, Non-Hodgkin Lymphoma, Unknown Primary

NCI ID

NCT03424603

Protocol IDs

STRO-001-BCM1
NCI-2018-00484

73.

A Phase 1 Study Evaluating the Safety, Tolerability and Pharmacokinetics of AMG 757 in Subjects With Small Cell Lung Cancer

Cancer Type

Lung Cancer, Skin Cancer (Non-Melanoma)

NCI ID

NCT03319940

Protocol IDs

20160323
NCI-2017-02043

74.

A Phase 1 Study of ABI-009 (NAB-RAPAMYCIN) in Pediatric Patients with Recurrent or Refractory Solid Tumors, including CNS Tumors as a Single Agent and in Combination with Temozolomide and Irinotecan

Cancer Type

Unknown Primary

NCI ID

NCT02975882

Protocol IDs

ADVL1514
ADVL1514
NCI-2016-01412
ADVL1514

75.

A Phase 1 Study of ALKS 4230 Administered Subcutaneously as Monotherapy and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors (ARTISTRY-2)

Cancer Type

Unknown Primary

NCI ID

NCT03861793

Protocol IDs

ALKS 4230-001
NCI-2019-02348

76.

A Phase 1 Study of ASP1951 in Subjects With Advanced Solid Tumors

Cancer Type

Lung Cancer, Prostate Cancer , Unknown Primary

NCI ID

NCT03799003

Protocol IDs

1951-CL-0101
NCI-2019-02414

77.

A Phase 1 Study of bb21217, an Anti-BCMA CAR T Cell Drug Product, in Relapsed and / or Refractory Multiple Myeloma

Cancer Type

Lymphoma, Multiple Myeloma

NCI ID

NCT03274219

Protocol IDs

CRB-402
NCI-2017-01861

78.

A Phase 1 Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (advSM) and Relapsed or Refractory Myeloid Malignancies

Cancer Type

NCI ID

NCT02561988

Protocol IDs

BLU-285-2101
NCI-2016-00075
2015-001661-12

79.

A Phase 1 Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Malignancies

Cancer Type

Head and Neck Cancer, Lung Cancer

NCI ID

NCT03329950

Protocol IDs

Treatment Sites (2)

Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242

Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355

80.

A Phase 1 Study of DS-3032b in Combination With Quizartinib in Subjects With FLT3-ITD Mutant Acute Myeloid Leukemia That Are Relapsed / Refractory, or Newly Diagnosed and Unfit for Intensive Chemotherapy

Cancer Type

NCI ID

NCT03552029

Protocol IDs

DS3032-A-U105
NCI-2018-01454

81.

A Phase 1 Study of Ipilimumab in Combination with Decitabine in Relapsed or Refractory Myelodysplastic Syndrome / Acute Myeloid Leukemia

Cancer Type

Myelodysplastic Syndromes (MDS)

NCI ID

NCT02890329

Protocol IDs

Treatment Sites (14)

Atlanta Cancer Care - Conyers
Conyers
404-303-3355

Atlanta Cancer Care - Stockbridge
Jonesboro
Andrena Jefferson
678 466-2069

Atlanta Cancer Care - Tower
Atlanta
404-303-3355

Atlanta Gynecologic Oncology
Atlanta
Jen Cuvo
404-303-3355

Georgia Cancer Specialists - Athens
Athens
Cynthia Pirkle

Georgia Cancer Specialists - Canton
Canton

Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242

Georgia Cancer Specialists - Kennestone
Marietta
Greta Dudley

Georgia Cancer Specialists - Macon-Coliseum
Macon
Sonia Hernandez
478-745-6130 x8152

Georgia Cancer Specialists - Stemmer
Decatur
Nina Patel
770-496-5555

Georgia Gynecologic Oncology
Atlanta
Jen Cuvo
404-303-3355

Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355

Northside Hospital Cancer Institute - Forsyth
Cumming
404-303-3355

University Gynecologic Oncology
Atlanta
Jen Cuvo
404-303-3355

82.

A Phase 1 Study of MK-3475 (Pembrolizumab) in Combination with Recombinant Interleukin-12 in Patients with Solid Tumors

Cancer Type

Unknown Primary

NCI ID

NCT03030378

Protocol IDs

10061
10061
NCI-2017-00091
HCC 17-003

83.

A Phase 1 Study of Oral LOXO-292 in Patients With Advanced Solid Tumors, Including RET-Fusion Non-Small Cell Lung Cancer, Medullary Thyroid Cancer, and Other Tumors With Increased RET Activity

Cancer Type

Colon/Rectal Cancer, Lung Cancer, Skin Cancer (Non-Melanoma), Thyroid Cancer, Unknown Primary

NCI ID

NCT03157128

Protocol IDs

LOXO-RET-17001
NCI-2017-00976
2017-000800-59

84.

A Phase 1 Study of Palbociclib in Combination with Cisplatin or Carboplatin in Advanced Solid Malignancies

Cancer Type

Unknown Primary

NCI ID

NCT02897375

Protocol IDs

Winship3263-16
NCI-2016-01037
IRB00089583

85.

A Phase 1 Study of Pevonedistat (MLN4924), a NEDD8 Activating Enzyme (NAE) Inhibitor, in Combination with Temozolomide and Irinotecan in Pediatric Patients with Recurrent or Refractory Solid Tumors

Cancer Type

Lymphoma

NCI ID

NCT03323034

Protocol IDs

ADVL1615
ADVL1615
NCI-2017-01229
ADVL1615

86.

A Phase 1 Study of RGX-104, a Small Molecule LXR Agonist, in Patients With Advanced Solid Malignancies and Lymphoma With an Expansion in Select Malignancies

Cancer Type

Unknown Primary

NCI ID

NCT02922764

Protocol IDs

RGX-104-001
NCI-2017-00226

87.

A Phase 1 Study of Selinexor (KPT-330), a Selective XPO1 Inhibitor, in Recurrent and Refractory Pediatric Solid Tumors, Including CNS Tumors

Cancer Type

Brain Cancer , Eye Cancer, Non-Hodgkin Lymphoma, Unknown Primary

NCI ID

NCT02323880

Protocol IDs

ADVL1414
NCI-2014-02410

88.

A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma

Cancer Type

Bone and Soft Tissue (including Sarcoma), Chondrosarcoma

NCI ID

NCT02601937

Protocol IDs

EZH-102
NCI-2015-02224

89.

A Phase 1 Study of the Safety and Pharmacokinetics of Venetoclax in Pediatric and Young Adult Patients With Relapsed or Refractory Malignancies

Cancer Type

Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Leukemia, Lymphoma, Neuroblastoma

NCI ID

NCT03236857

Protocol IDs

M13-833
NCI-2017-02027
2017-000439-14

90.

A PHASE 1 STUDY TO EVALUATE THE EFFECT OF HEPATIC IMPAIRMENT ON THE PHARMACOKINETICS AND SAFETY OF LORLATINIB IN ADVANCED CANCER PATIENTS

Cancer Type

Lymphoma, Unknown Primary

NCI ID

NCT03726333

Protocol IDs

B7461009
NCI-2019-01060
HEPATIC IMPAIRMENT
lorlatinib HEPATIC IMPAIRMENT

91.

A Phase 1 Study Using Nab-Paclitaxel (Abraxane®) in Combination with Gemcitabine for Pediatric Relapsed and Refractory Solid Tumors

Cancer Type

NCI ID

NCT03507491

Protocol IDs

AFLACST1603
NCI-2018-00465
IRB00098777

92.

A Phase 1 Study Using Simvastatin in Combination With Topotecan and Cyclophosphamide in Relapsed and/or Refractory Pediatric Solid and CNS Tumors

Cancer Type

Unknown Primary

NCI ID

NCT02390843

Protocol IDs

Treatment Sites (1)

Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180

93.

A Phase 1 Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of CPX-351 (Daunorubicin and Cytarabine) Liposome for Injection Treatment in Adult Patients With Hematologic Malignancies

Cancer Type

Lymphoma, Myelodysplastic Syndromes (MDS)

NCI ID

NCT03555955

Protocol IDs

Treatment Sites (2)

Atlanta Cancer Care - Conyers
Conyers
404-303-3355

Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355

94.

A Phase 1 Trial using Everolimus in Combination with Nelarabine, Cyclophosphamide and Etoposide in Relapsed T cell Lymphoblastic Leukemia / Lymphoma

Cancer Type

Lymphoma

NCI ID

NCT03328104

Protocol IDs

AflacLL1602
NCI-2017-01717

95.

A Phase 1, Dose Escalation and Expansion Study of Engineered Donor Grafts Derived From Mobilized Peripheral Blood (OrcaGraft), With Single Agent Graft Versus-host Disease Prophylaxis, in Recipients Undergoing Myeloablative Allogeneic Hematopoietic Cell Transplantation for Hematologic Malignancies

Cancer Type

Myelodysplastic Syndromes (MDS)

NCI ID

NCT03802695

Protocol IDs

OGFT001-001
NCI-2019-01953

96.

A Phase 1, First in Human, Dose Escalation Study of MGD006, a CD123 x CD3 Dual Affinity Re-Targeting (DART) Bi-Specific Antibody Based Molecule, in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Cancer Type

Leukemia

NCI ID

NCT02152956

Protocol IDs

CP-MGD006-01
NCI-2014-01526

97.

A Phase 1, First-in-Human, Open-Label, Dose Escalation and Expansion Study of CUE-101 Monotherapy in Patients With HPV+ Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)

Cancer Type

Skin Cancer (Non-Melanoma), Unknown Primary

NCI ID

NCT03978689

Protocol IDs

Cue-101-01
NCI-2019-04589

98.

A Phase 1, Multicenter, Open-Label Study of JCAR017, CD19-targeted Chimeric Antigen Receptor (CAR) T Cells, for Relapsed and Refractory (R / R) B-cell Non-Hodgkin Lymphoma (NHL)

Cancer Type

Lymphoma, Non-Hodgkin Lymphoma

NCI ID

NCT02631044

Protocol IDs

Treatment Sites (1)

Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355

99.

A Phase 1, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HMPL-689 in Patients With Relapsed or Refractory Lymphoma

Cancer Type

NCI ID

NCT03786926

Protocol IDs

2018-689-US001
NCI-2019-01158
2018-689-00US1

100.

A Phase 1, Open-label, Dose Finding Study of CC-93269, a BCMA X CD3 T Cell Engaging Antibody, in Subjects With Relapsed and Refractory Multiple Myeloma.

Cancer Type

Lymphoma, Multiple Myeloma

NCI ID

NCT03486067

Protocol IDs

CC-93269-MM-001
NCI-2018-02280
2017-003448-19
U1111-1210-6325

101.

A Phase 1, Open-Label, Dose-Escalation and Cohort Expansion First-in-Human Study of the Safety, Tolerability, Activity and Pharmacokinetics of REGN3767 (Anti-LAG-3 mAb) Administered Alone or in Combination With REGN2810 (Anti-PD-1 mAb) in Patients With Advanced Malignancies

Cancer Type

Lymphoma, Unknown Primary

NCI ID

NCT03005782

Protocol IDs

R3767-ONC-1613
NCI-2017-00409
2016-002789-30

102.

A Phase 1, Open-Label, Dose-Finding Study Of ASN007 In Patients With Advanced Solid Tumors

Cancer Type

Colon/Rectal Cancer, Lung Cancer, Melanoma, Pancreatic Cancer, Skin Cancer (Non-Melanoma), Unknown Primary

NCI ID

NCT03415126

Protocol IDs

ASN007-101
NCI-2018-00820

103.

A Phase 1, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Ascending Doses of AZD5991 in Subjects With Relapsed or Refractory Haematologic Malignancies

Cancer Type

Hodgkin Lymphoma, Leukemia, Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes (MDS), Non-Hodgkin Lymphoma, Skin Cancer (Non-Melanoma), Unknown Primary

NCI ID

NCT03218683

Protocol IDs

Treatment Sites (1)

Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180

104.

A Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination With Atezolizumab in Patients With Selected Incurable Cancers

Cancer Type

Oral Cancer

NCI ID

NCT02655822

Protocol IDs

Treatment Sites (1)

Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180

105.

A Phase 1/2 Study of INCB053914 in Subjects With Advanced Malignancies

Cancer Type

Unknown Primary

NCI ID

NCT02587598

Protocol IDs

INCB 53914-101
NCI-2015-01975

106.

A Phase 1/2 Study of MK-1775 in Combination With Irinotecan in Children, Adolescents, and Young Adults With Relapsed or Refractory Solid Tumors

Cancer Type

Unknown Primary

NCI ID

NCT02095132

Protocol IDs

Treatment Sites (1)

Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853

107.

A Phase 1/2 Study of Nivolumab in Children, Adolescents, and Young Adults With Recurrent or Refractory Solid Tumors as a Single Agent and in Combination With Ipilimumab

Cancer Type

Unknown Primary

NCI ID

NCT02304458

Protocol IDs

Treatment Sites (1)

Aflac Cancer and Blood Disorders Center of Children’s at Egleston
Atlanta
Howard M. Katzenstein, MD
404-785-0853

108.

A Phase 1/2, Open-label, Multicenter, Dose Escalation and Dose Expansion Study of NKTR-214 and Nivolumab in Patients With Select Locally Advanced or Metastatic Solid Tumor Malignancies.

Cancer Type

Kidney Cancer, Lung Cancer, Melanoma

NCI ID

NCT02983045

Protocol IDs

Treatment Sites (1)

Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180

109.

A Phase 1/2A Open-Label, Multi-Dose, Multi-Center Escalation and Exploratory Study of Cerdulatinib (PRT062070) in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) or B Cell or T Cell Non-Hodgkin Lymphoma (NHL)

Cancer Type

Non-Hodgkin Lymphoma

NCI ID

NCT01994382

Protocol IDs

Treatment Sites (1)

Gwinnett Medical Center
Lawrenceville
404-851-2340

110.

A Phase 1/2a Study of BMS-986205 Administered in Combination With Nivolumab (BMS-936558, Anti-PD-1 Monoclonal Antibody) in Advanced Malignant Tumors

Cancer Type

Unknown Primary

NCI ID

NCT02658890

Protocol IDs

Treatment Sites (2)

Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242

Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355

111.

A Phase 1b / 2 Open Label, Dose Escalation and Expansion Study of the Glutaminase Inhibitor CB-839 in Combination With the PARP Inhibitor Talazoparib in Patients With Advanced or Metastatic Solid Tumors

Cancer Type

Breast Cancer, Kidney Cancer, Unknown Primary

NCI ID

NCT03875313

Protocol IDs

CX-839-011
NCI-2019-02256

112.

A Phase 1b / 2 Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics,Pharmacodynamics, and Efficacy of AMG 592 inAdult Subjects With Steroid Refractory Chronic Graft Versus Host Disease

Cancer Type

NCI ID

NCT03422627

Protocol IDs

20160283
NCI-2018-00330
2017-000763-33

113.

A Phase 1b / 2 Open-label Study To Evaluate Safety, Clinical Activity, Pharmacokinetics And Pharmacodynamics Of Avelumab (msb0010718c) In Combination With Other Cancer Immunotherapies In Patients With Advanced Malignancies

Cancer Type

Breast Cancer, Lung Cancer, Melanoma, Ovarian Cancer, Skin Cancer (Non-Melanoma), Stomach/ Gastric Cancer, Unknown Primary

NCI ID

NCT02554812

Protocol IDs

B9991004
NCI-2015-02263
2015-002552-27
JAVELIN MEDLEY
s16-02110

114.

A Phase 1b / 2 Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of Oleclumab (MEDI9447) With or Without Durvalumab in Combination With Chemotherapy in Subjects With Metastatic Pancreatic Ductal Adenocarcinoma

Cancer Type

Pancreatic Cancer, Unknown Primary

NCI ID

NCT03611556

Protocol IDs

D6070C00005
NCI-2018-01724
D6070C00005

115.

A Phase 1b / 2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of EQ001 in Subjects With Newly Diagnosed Acute Graft Versus Host Disease

Cancer Type

Bone and Soft Tissue (including Sarcoma)

NCI ID

NCT03763318

Protocol IDs

EQ001-aGVHD-001
NCI-2019-01124

116.

A Phase 1b / 2, Open Label, Dose Escalation and Expansion Study of the Glutaminase Inhibitor Telaglenastat (CB-839) in Combination With CDK4 / 6 Inhibitor Palbociclib in Patients With Advanced or Metastatic Solid Tumors

Cancer Type

NCI ID

NCT03965845

Protocol IDs

CX-839-012
NCI-2019-05094

117.

A Phase 1b / 2, Open-Label, Multicenter Dose-Escalation and Dose-Expansion Study of the Combination of RMC-4630 and Cobimetinib in Adult Participants With Relapsed / Refractory Solid Tumors With Specific Genomic Aberrations

Cancer Type

Unknown Primary

NCI ID

NCT03989115

Protocol IDs

RMC-4630-02
NCI-2019-04826

118.

A Phase 1b / 2a Pilot Randomized Study to Evaluate the Safety and Tolerability of Autologous T-Cells Expressing Enhanced TCRs (T Cell Receptors) Specific for NY-ESO-1 / LAGE-1a (GSK3377794) Alone, or in Combination With Pembrolizumab in HLA-A2+ Participants With NY-ESO-1- or LAGE-1a-Positive Advanced or Recurrent Non-Small Cell Lung Cancer

Cancer Type

Lung Cancer, Unknown Primary

NCI ID

NCT03709706

Protocol IDs

208471
NCI-2018-03721

119.

A Phase 1b Dose-escalation and Dose-expansion Study of Enfortumab Vedotin (ASG-22CE) in Combination With Immune Checkpoint Inhibitor (CPI) Therapy for Treatment of Patients With Locally Advanced or Metastatic Urothelial Cancer

Cancer Type

Bladder Cancer, Kidney Cancer, Unknown Primary

NCI ID

NCT03288545

Protocol IDs

SGN22E-002
NCI-2017-01927

120.

A Phase 1B Study of AZD9291 in Combination with Navitoclax in EGFR-Mutant Non-Small Cell Lung Cancer following Resistance to Initial EGFR Kinase Inhibitor

Cancer Type

Lung Cancer

NCI ID

NCT02520778

Protocol IDs

9903
9903
NCI-2015-01270
16-714

121.

A Phase 1b, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients With Solid Tumors Likely to Express NaPi2b

Cancer Type

NCI ID

NCT03319628

Protocol IDs

XMT-1536-1
NCI-2018-00402

122.

A Phase 1b-2 Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab, and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in Patients With B-Cell Lymphoid Malignancies

Cancer Type

Leukemia, Lymphoma

NCI ID

NCT03420183

Protocol IDs

CIRM-0001
NCI-2018-00270

123.

A Phase 1b-2 Study of the ROR1-Targeting Monoclonal Antibody, Cirmtuzumab, and the Bruton Tyrosine Kinase Inhibitor, Ibrutinib, in Patients with B-Cell Lymphoid Malignancies

Cancer Type

NCI ID

NCT03088878

Protocol IDs

170127
NCI-2018-01703
NCT03420183

124.

A Phase 2 / 3, Multicenter, randOmized, Double-blind, Placebo-controlled, stUdy to evaLuate the Safety and Efficacy of Alpha-1 AntiTrypsin for the prEvention of Graft Versus-host Disease in Patients Receiving Hematopoietic Cell Transplant (MODULAATE Study)

Cancer Type

Myelodysplastic Syndromes (MDS)

NCI ID

NCT03805789

Protocol IDs

CSL964_2001
NCI-2019-03310
2018-000329-29

125.

A Phase 2 Efficacy and Safety Trial of ADU-S100 and Anti-PD1 in Adults With Head and Neck Cancer

Cancer Type

Unknown Primary

NCI ID

NCT03937141

Protocol IDs

ADU-CL-20
NCI-2019-04759

126.

A Phase 2 Front-Line PET / CT-2 Response-Adapted Brentuximab Vedotin and Nivolumab Incorporated and Radiation-Free Management of Early Stage Classical Hodgkin Lymphoma (cHL)

Cancer Type

Lymphoma

NCI ID

NCT03712202

Protocol IDs

18157
NCI-2018-01592

127.

A Phase 2 Randomized Study of Irinotecan / Temozolomide / Dinutuximab with or without Eflornithine (DFMO) in Children with Relapsed, Refractory or Progressive Neuroblastoma

Cancer Type

Neuroblastoma

NCI ID

NCT03794349

Protocol IDs

ANBL1821
ANBL1821
NCI-2018-03377

128.

A Phase 2 Study of Anti-PD-L1 Antibody (Atezolizumab) in Alveolar Soft Part Sarcoma

Cancer Type

Bone and Soft Tissue (including Sarcoma)

NCI ID

NCT03141684

Protocol IDs

Treatment Sites (1)

Emory University Hospital - Midtown
Atlanta
Scott Edelman
404-686-4411

129.

A Phase 2 Study of Atezolizumab and Cobimetinib in PD-1 / PD-L1 Inhibitor Resistant or Refractory Non-Small Cell Lung Cancer

Cancer Type

NCI ID

NCT03600701

Protocol IDs

10166
10166
NCI-2017-01812

130.

A Phase 2 Study of Dabrafenib (NSC# 763760) with Trametinib (NSC# 763093) after Local Irradiation in Newly-Diagnosed BRAF V600-Mutant High-Grade Glioma (HGG)

Cancer Type

NCI ID

NCT03919071

Protocol IDs

ACNS1723
ACNS1723
NCI-2019-02289

131.

A Phase 2 Study of Inotuzumab Ozogamicin (NSC# 772518) in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL)

Cancer Type

Lymphoma

NCI ID

NCT02981628

Protocol IDs

AALL1621
AALL1621
NCI-2016-01494
AALL1621

132.

A Phase 2 Study of Lenvatinib in Combination with Radioactive Iodine Therapy in Patients with Progressive RAI-Sensitive Differentiated Thyroid Cancer

Cancer Type

Thyroid Cancer

NCI ID

NCT03506048

Protocol IDs

Winship4271-18
NCI-2018-00144
IRB00101617

133.

A Phase 2 Study of Neoadjuvant Cabozantinib in Patients with Locally Advanced Non-Metastatic Clear Cell Renal Cell Carcinoma

Cancer Type

Kidney Cancer, Unknown Primary

NCI ID

NCT04022343

Protocol IDs

Winship4643-19
NCI-2019-02253
IRB00110583

134.

A Phase 2 Study of Olaparib Monotherapy in Participants With Previously Treated, Homologous Recombination Repair Mutation (HRRm) or Homologous Recombination Deficiency (HRD) Positive Advanced Cancer

Cancer Type

Unknown Primary

NCI ID

NCT03742895

Protocol IDs

7339-002
NCI-2018-03519
2018-003007-19
MK-7339-002

135.

A Phase 2 Study of Reduced Therapy for Newly Diagnosed Average-Risk WNT-Driven Medulloblastoma Patients

Cancer Type

NCI ID

NCT02724579

Protocol IDs

ACNS1422
ACNS1422
NCI-2016-00150
ACNS1422

136.

A Phase 2 Study of the JAK1/JAK2 Inhibitor Ruxolitinib With Chemotherapy in Children With De Novo High-Risk CRLF2-Rearranged and/or JAK Pathway-Mutant Acute Lymphoblastic Leukemia

Cancer Type

Acute Lymphoblastic Leukemia

NCI ID

NCT02723994

Protocol IDs

INCB 18424-269
NCI-2016-01687
AALL1521

137.

A Phase 2 Study of the MEK Inhibitor Trametinib (NSC# 763093) in Children with Relapsed or Refractory Juvenile Myelomonocytic Leukemia

Cancer Type

Myelodysplastic Syndromes (MDS)

NCI ID

NCT03190915

Protocol IDs

ADVL1521
ADVL1521
NCI-2017-00921
ADVL1521

138.

A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 Mutant Advanced Solid Tumors

Cancer Type

NCI ID

NCT03212274

Protocol IDs

10129
10129
NCI-2017-01182
2000023083

139.

A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis

Cancer Type

Myelodysplastic Syndromes (MDS)

NCI ID

NCT02718300

Protocol IDs

INCB 50465-201
NCI-2016-01146

140.

A Phase 2 Study of Veliparib (ABT-888) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients with Newly Diagnosed High-Grade Glioma (HGG) without H3 K27M or BRAFV600E Mutations

Cancer Type

NCI ID

NCT03581292

Protocol IDs

ACNS1721
ACNS1721
NCI-2018-01361

141.

A Phase 2 Study To Evaluate Safety And Anti-tumor Activity Of Avelumab In Combination With Talazoparib In Patients With Brca Or Atm Mutant Tumors

Cancer Type

Unknown Primary

NCI ID

NCT03565991

Protocol IDs

Treatment Sites (13)

Atlanta Cancer Care - Alpharetta
Alpharetta
Kristin Sieverding
770-777-1315

Atlanta Cancer Care - Conyers
Conyers
404-303-3355

Atlanta Cancer Care - Cumming
Cumming
Renee Gaiter
770-205-5292 x1041

Atlanta Cancer Care - Decatur
Decatur
404-303-3355

Atlanta Cancer Care - Stockbridge
Jonesboro
Andrena Jefferson
678 466-2069

Atlanta Cancer Care - Tower
Atlanta
404-303-3355

Georgia Cancer Specialists - Athens
Athens
Cynthia Pirkle

Georgia Cancer Specialists - Canton
Canton

Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242

Georgia Cancer Specialists - Kennestone
Marietta
Greta Dudley

Georgia Cancer Specialists - Macon-Coliseum
Macon
Sonia Hernandez
478-745-6130 x8152

Georgia Cancer Specialists - Stemmer
Decatur
Nina Patel
770-496-5555

Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355

142.

A Phase 2, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Participants With Advanced Gastric Cancer (FRACTION-Gastric Cancer)

Cancer Type

Stomach/ Gastric Cancer

NCI ID

NCT02935634

Protocol IDs

CA018-003
NCI-2017-00025
2016-002807-24

143.

A Phase 2, Multicenter Study to Determine the Efficacy and Safety of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma

Cancer Type

Lymphoma, Multiple Myeloma

NCI ID

NCT03361748

Protocol IDs

BB2121-MM-001
NCI-2017-02488
U1111-1202-5554
2017-002245-29

144.

A Phase 2, Multicenter Study to Evaluate the Efficacy and Safety Using Autologous Tumor Infiltrating Lymphocytes (LN-145) in Patients With Recurrent, Metastatic or Persistent Cervical Carcinoma

Cancer Type

Cervical Cancer

NCI ID

NCT03108495

Protocol IDs

Treatment Sites (1)

Georgia Cancer Center at Augusta University
Augusta

145.

A Phase 2, Multicenter, Open-label Study to Assess Safety and Preliminary Activity of Eribulin Mesylate in Pediatric Subjects With Relapsed / Refractory Rhabdomyosarcoma (RMS), Non-rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) and Ewing Sarcoma (EWS)

Cancer Type

Ewing Sarcoma

NCI ID

NCT03441360

Protocol IDs

E7389-G000-223
NCI-2018-00749

146.

A Phase 2, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of CDX-3379 in Combination With Cetuximab in Patients With Advanced Head and Neck Squamous Cell Carcinoma

Cancer Type

Unknown Primary

NCI ID

NCT03254927

Protocol IDs

CDX3379-04
NCI-2017-01709

147.

A Phase 2, Multicohort, Open-label, Multicenter Study to Determine the Efficacy and Safety of bb2121 in Subjects With Relapsed and Refractory Multiple Myeloma and in Subjects With High-Risk Multiple Myeloma Having Progressed Within One Year of Initial Treatment (KarMMa-2)

Cancer Type

Lymphoma, Multiple Myeloma

NCI ID

NCT03601078

Protocol IDs

BB2121-MM-002
NCI-2018-01730
U1111-1216-4209
2018-000264-28

148.

A Phase 2, Non-randomized, Open Label, Single Arm, Multi-center Study Of Talazoparib For Neoadjuvant Treatment Of Germline Brca1 / 2 Mutation Patients With Early Triple-negative Breast Cancer

Cancer Type

Breast Cancer

NCI ID

NCT03499353

Protocol IDs

C3441020
NCI-2018-01223
TALAZOPARIB NEOADJ BC

149.

A Phase 2, Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600E-mutant Non-small Cell Lung Cancer

Cancer Type

Lung Cancer

NCI ID

NCT03915951

Protocol IDs

ARRAY-818-202
NCI-2019-02644

150.

A Phase 2, Open-label Study of Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma

Cancer Type

Bladder Cancer, Kidney Cancer, Unknown Primary

NCI ID

NCT03397394

Protocol IDs

CO-338-085
NCI-2018-01112

151.

A Phase 2, Open-label Study of Zanubrutinib (BGB-3111) in Patients With Relapsed or Refractory Marginal Zone Lymphoma

Cancer Type

Lymphoma

NCI ID

NCT03846427

Protocol IDs

BGB-3111-214 (MAGNOLIA)
NCI-2019-01421

152.

A Phase 2, Open-label, 2-arm, Response Rate Study Of Talazoparib In Men With Dna Repair Defects And Metastatic Castration-resistant Prostate Cancer Who Previously Received Taxane-based Chemotherapy And Progressed On At Least 1 Novel Hormonal Agent (Enzalutamide And / or Abiraterone Acetate / Prednisone)

Cancer Type

Prostate Cancer , Unknown Primary

NCI ID

NCT03148795

Protocol IDs

MDV3800-06
NCI-2017-01403
C3441006
2016-002036-32

153.

A Phase 2, Open-Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement

Cancer Type

Eye Cancer, Leukemia

NCI ID

NCT03011372

Protocol IDs

Treatment Sites (1)

Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180

154.

A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Cancer Type

Lymphoma, Multiple Myeloma

NCI ID

NCT02899052

Protocol IDs

M15-538
NCI-2016-01672

155.

A Phase 2, Open-label, Multicenter, Study of an Immunotherapeutic Treatment, DPX-Survivac in Combination With Low Dose Cyclophosphamide and Pembrolizumab, in Subjects With Selected Advanced and Recurrent Solid Tumours.

Cancer Type

Lung Cancer, Ovarian Cancer, Unknown Primary

NCI ID

NCT03836352

Protocol IDs

P1719-SUR-Z11
NCI-2019-03013
Keynote 903

156.

A Phase 2, Open-Label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects With Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations

Cancer Type

Bladder Cancer, Kidney Cancer

NCI ID

NCT02872714

Protocol IDs

INCB 54828-201
NCI-2016-01513

157.

A Phase 2, Prospective, Randomized, Open-Label Study on the Efficacy of Defibrotide Added to Standard of Care Immunoprophylaxis for the Prevention of Acute Graft-versus-Host-Disease in Adult and Pediatric Patients After Allogeneic Hematopietic Stem Cell Transplant

Cancer Type

Bone and Soft Tissue (including Sarcoma), Myelodysplastic Syndromes (MDS)

NCI ID

NCT03339297

Protocol IDs

JZP963-201
NCI-2018-00520

158.

A Phase 2, Randomized, Biomarker-driven, Clinical Study on Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML)

Cancer Type

Leukemia

NCI ID

NCT02520011

Protocol IDs

TPI-ALV-201
NCI-2015-02082

159.

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib in Patients With Metastatic Castration-Resistant Prostate Cancer

Cancer Type

Prostate Cancer , Unknown Primary

NCI ID

NCT03706365

Protocol IDs

Treatment Sites (13)

Atlanta Cancer Care - Alpharetta
Alpharetta
Kristin Sieverding
770-777-1315

Atlanta Cancer Care - Conyers
Conyers
404-303-3355

Atlanta Cancer Care - Cumming
Cumming
Renee Gaiter
770-205-5292 x1041

Atlanta Cancer Care - Decatur
Decatur
404-303-3355

Atlanta Cancer Care - Stockbridge
Jonesboro
Andrena Jefferson
678 466-2069

Atlanta Cancer Care - Tower
Atlanta
404-303-3355

Georgia Cancer Specialists - Athens
Athens
Cynthia Pirkle

Georgia Cancer Specialists - Canton
Canton

Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242

Georgia Cancer Specialists - Kennestone
Marietta
Greta Dudley

Georgia Cancer Specialists - Macon-Coliseum
Macon
Sonia Hernandez
478-745-6130 x8152

Georgia Cancer Specialists - Stemmer
Decatur
Nina Patel
770-496-5555

Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355

160.

A Phase 2, Randomized, Multi-Institutional Study of Nivolumab and Ipilimumab versus Nivolumab, Ipilimumab, and Stereotactic Body Radiation Therapy for Metastatic Merkel Cell Carcinoma

Cancer Type

Skin Cancer (Non-Melanoma)

NCI ID

NCT03071406

Protocol IDs

MCC-18786
NCI-2017-00427

161.

A Phase 2, Randomized, Non-Comparative, Open-Label Study of NKTR-214 in Combination With Nivolumab and of Chemotherapy in Cisplatin Ineligible, Locally Advanced or Metastatic Urothelial Cancer Patients With Low PD-L1 Expression

Cancer Type

Bladder Cancer, Kidney Cancer, Unknown Primary

NCI ID

NCT03785925

Protocol IDs

18-214-10
NCI-2019-01752
CA045-012

162.

A Phase 2, Randomized, Open-label Study of Nivolumab or Nivolumab / BMS-986205 Alone or Combined With Intravesical BCG in Participants With BCG-Unresponsive, High-Risk, Non-Muscle Invasive Bladder Cancer

Cancer Type

Bladder Cancer

NCI ID

NCT03519256

Protocol IDs

CA209-9UT
NCI-2018-01177
2017-003581-27

163.

A Phase 2, Single Arm, Multicenter, Open Label Trial Combining Optune with Concurrent Bevacizumab in the Setting of Recurrent or Progressive Meningioma

Cancer Type

Brain Cancer

NCI ID

NCT02847559

Protocol IDs

NU 16C02
NCI-2016-01026
STU00203030

164.

A Phase 2, Single-Arm Study of Denosumab in Multiple Myeloma Patients with Renal Insufficiency

Cancer Type

Lymphoma, Multiple Myeloma

NCI ID

NCT02833610

Protocol IDs

15-571
NCI-2016-01375

165.

A Phase 2, Single-arm, Open-label Study of Single-agent Brentuximab Vedotin for Front-line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above

Cancer Type

Hodgkin Lymphoma

NCI ID

NCT01716806

Protocol IDs

SGN35-015

166.

A Phase 2a, Open-Label, Multi-Center Study to Assess the Efficacy and Safety of Marrow Infiltrating Lymphocytes - Non-Small Cell Lung Cancer (MILs™ - NSCLC) Alone or in Combination With Pembrolizumab in Subjects With Advanced Unresectable or Metastatic NSCLC Previously Treated With Anti-PD-1

Cancer Type

NCI ID

NCT04069936

Protocol IDs

CLN-P18001
NCI-2019-06384

167.

A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 With or Without Bendamustine and TGR-1202 Alone in Patients With Previously Treated Non-Hodgkin's Lymphoma

Cancer Type

Lymphoma

NCI ID

NCT02793583

Protocol IDs

UTX-TGR-205
NCI-2016-01433

168.

A Phase 3 Randomized Double-Blind Placebo-Controlled Study Investigating the Efficacy and Safety of Roxadustat (FG-4592) for Treatment of Anemia in Patients With Lower Risk Myelodysplastic Syndrome (MDS) With Low Red Blood Cell (RBC) Transfusion Burden (LTB)

Cancer Type

Myelodysplastic Syndromes (MDS)

NCI ID

NCT03263091

Protocol IDs

FGCL-4592-082
NCI-2017-02071

169.

A Phase 3 Randomized Open Label Study to Compare NKTR-214 Combined With Nivolumab to the Investigator's Choice of Sunitinib or Cabozantinib in Patients With Previously Untreated Advanced Renal Cell Carcinoma

Cancer Type

Kidney Cancer, Unknown Primary

NCI ID

NCT03729245

Protocol IDs

17-214-09
NCI-2019-01389
CA045002

170.

A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)

Cancer Type

Kidney Cancer

NCI ID

NCT03055013

Protocol IDs

Treatment Sites (2)

Nancy N. and J.C. Lewis Cancer & Research Pavilion at St. Joseph's/Candler
Savannah
Alaina Underberg
912-819-5778

Winship Cancer Institute of Emory University
Atlanta
Scott Edelman
404-778-5180

171.

A Phase 3 randomized study to assess the efficacy and safety of Ublituximab in combination with TGR-1202 compared to Obinutuzumab in combination with Chlorambucil in patients with Chronic Lymphocytic Leukemia (CLL)

Cancer Type

Leukemia

NCI ID

NCT02656303

Protocol IDs

UTX-TGR-304

172.

A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy

Cancer Type

NCI ID

NCT03959085

Protocol IDs

AALL1732
AALL1732
NCI-2019-02845

173.

A Phase 3 Randomized, Double Blind Study of Pembrolizumab Plus Gemcitabine / Cisplatin Versus Placebo Plus Gemcitabine / Cisplatin as First-Line Therapy in Participants With Advanced and / or Unresectable Biliary Tract Carcinoma

Cancer Type

NCI ID

NCT04003636

Protocol IDs

3475-966
NCI-2019-05779
2019-000944-82
MK-3475-966
KEYNOTE-966

174.

A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL)

Cancer Type

Neuroblastoma

NCI ID

NCT03126916

Protocol IDs

ANBL1531
ANBL1531
NCI-2016-01734

175.

A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors

Cancer Type

Germ Cell Tumor

NCI ID

NCT03067181

Protocol IDs

AGCT1531
AGCT1531
NCI-2017-00178
AGCT1531

176.

A Phase 3 Study of Pembrolizumab in Combination With Carboplatin / Taxane (Paclitaxel or Nab-paclitaxel) Followed by Pembrolizumab With or Without Maintenance Olaparib in the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

Cancer Type

NCI ID

NCT03976362

Protocol IDs

7339-008
NCI-2019-03995
KEYLYNK-008
MK-7339-008
2018-004721-88
KEYLNK-008
194894

177.

A Phase 3 Trial Investigating Blinatumomab ( NSC# 765986) in Combination with Chemotherapy in Patients with Newly Diagnosed Standard Risk or Down Syndrome B-Lymphoblastic Leukemia (B-ALL) and the Treatment of Patients with Localized B-Lymphoblastic Lymphoma (B-LLy)

Cancer Type

Lymphoma

NCI ID

NCT03914625

Protocol IDs

AALL1731
AALL1731
NCI-2019-02187

178.

A Phase 3, Interventional, Randomized, Multicenter, Open-Label Study of DCC-2618 vs Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumors After Treatment With Imatinib

Cancer Type

Colon/Rectal Cancer

NCI ID

NCT03673501

Protocol IDs

Treatment Sites (2)

Georgia Cancer Specialists - CenterPointe
Sandy Springs
Anila Lokhandwala
404-256-4777 ext 9242

Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355

179.

A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination With Azacitidine in Subjects = 18 Years of Age With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation

Cancer Type

NCI ID

NCT03173248

Protocol IDs

AG120-C-009
NCI-2017-02366

180.

A Phase 3, Multicenter, Randomized, Double-blind Study to Compare the Efficacy and Safety of Oral Azacitidine Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in Subjects With Red Blood Cell Transfusion-dependent Anemia and Thrombocytopenia Due to IPSS Lower-risk Myelodysplastic Syndromes.

Cancer Type

Myelodysplastic Syndromes (MDS)

NCI ID

NCT01566695

Protocol IDs

AZA-MDS-003
2012-002471-34

181.

A Phase 3, Multicenter, Randomized, Double-blind, Double-dummy, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Compared to Valganciclovir for the Treatment of Cytomegalovirus (CMV) Infection in Hematopoietic Stem Cell Transplant Recipients

Cancer Type

NCI ID

NCT02927067

Protocol IDs

SHP620-302
NCI-2017-00422
2015-004726-34

182.

A Phase 3, Multicenter, Randomized, Open-label Study to Compare the Efficacy and Safety of bb2121 Versus Standard Triplet Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM) (KarMMa-3)

Cancer Type

Lymphoma, Multiple Myeloma

NCI ID

NCT03651128

Protocol IDs

Treatment Sites (2)

Atlanta Cancer Care - Conyers
Conyers
404-303-3355

Northside Hospital Cancer Institute
Atlanta
Northside Hospital Central Research Department
404-303-3355

183.

A Phase 3, Multicenter, Randomized, Open-label, Active-controlled Study to Assess the Efficacy and Safety of Maribavir Treatment Compared to Investigator-assigned Treatment in Transplant Recipients With Cytomegalovirus (CMV) Infections That Are Refractory or Resistant to Treatment With Ganciclovir, Valganciclovir, Foscarnet, or Cidofovir

Cancer Type

NCI ID

NCT02931539

Protocol IDs

SHP620-303
NCI-2016-01720
2015-004725-13

184.

A Phase 3, Open-Label, Randomized, Active-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Gemcitabine Plus Cisplatin Chemotherapy in First-Line Treatment of Participants With Unresectable or Metastatic Cholangiocarcinoma With FGFR2 Rearrangement (FIGHT-302)

Cancer Type

NCI ID

NCT03656536

Protocol IDs

INCB 54828-302
NCI-2019-01725

185.

A Phase 3, Randomized, Adaptive Study Comparing the Efficacy and Safety of Defibrotide vs Best Supportive Care in the Prevention of Hepatic Veno-Occlusive Disease in Adult and Pediatric Patients Undergoing Hematopoietic Stem Cell Transplant

Cancer Type

NCI ID

NCT02851407

Protocol IDs

15-007
NCI-2016-01249

186.

A Phase 3, Randomized, Comparator-controlled Clinical Trial to Study the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in Participants With High-risk Non-muscle Invasive Bladder Cancer (HR NMIBC) That is Persistent or Recurrent Following BCG Induction (KEYNOTE-676)

Cancer Type

NCI ID

NCT03711032

Protocol IDs

3475-676
NCI-2019-00740
2018-001967-22
MK-3475-676

187.

A Phase 3, Randomized, Controlled, Open-label, Clinical Study of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Low-Blast Acute Myelogenous Leukemia

Cancer Type

Myelodysplastic Syndromes (MDS)

NCI ID

NCT03268954

Protocol IDs

Pevonedistat-3001
NCI-2017-02059
U1111-1189-8055
2017-000318-40
JapicCTI-183848
MOH_2018-02-04_002154

188.

A Phase 3, Randomized, Double-blind Study of Adjuvant Nivolumab Versus Placebo for Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation

Cancer Type

NCI ID

NCT03383458

Protocol IDs

CA209-9DX
NCI-2018-00502

189.

A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF TALAZOPARIB WITH ENZALUTAMIDE IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER

Cancer Type

Prostate Cancer , Unknown Primary

NCI ID

NCT03395197

Protocol IDs

C3441021
NCI-2018-01651
TALAPRO-2
2017-003295-31

190.

A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Therapy Following Surgery and Radiation in Participants With High-risk Locally Advanced Cutaneous Squamous Cell Carcinoma (LA cSCC) (KEYNOTE-630)

Cancer Type

Skin Cancer (Non-Melanoma), Unknown Primary

NCI ID

NCT03833167

Protocol IDs

3475-630
NCI-2019-01629
MK-3475-630
2018-001974-76
KEYNOTE-630

191.

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Superoxide Dismutase Mimetic GC4419 to Reduce Severe Oral Mucositis (SOM) Associated With Chemoradiotherapy for Locally Advanced, Non-Metastatic Head and Neck Cancer

Cancer Type

Unknown Primary

NCI ID

NCT03689712

Protocol IDs

GTI-4419-301
NCI-2018-02271

192.

A Phase 3, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to Chlorambucil in Combination With Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

Cancer Type

Leukemia

NCI ID

Protocol IDs

NCT01980875

193.

A Phase 3, Randomized, Open-label Study of NKTR-214 Combined With Nivolumab Versus Nivolumab in Participants With Previously Untreated Unresectable or Metastatic Melanoma

Cancer Type

Melanoma, Skin Cancer (Non-Melanoma), Unknown Primary

NCI ID

NCT03635983

Protocol IDs

CA045-001
NCI-2018-02224
17-214-08
2018-001423-40

194.

A Phase 3B Randomized Study of Lenalidomide (CC-5013) Plus Rituximab Maintenance Therapy Followed by Lenalidomide Single-agent Maintenance Versus Rituximab Maintenance in Subjects With Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma

Cancer Type

Lymphoma

NCI ID

NCT01996865

Protocol IDs

CC-5013-NHL-008

195.